Physician

Jay S. Herbst, M.D.

According to 2025 Medicare claims, Jay Herbst, M.D. (NPI: 1710047097) practices dermatology in the Punta Gorda, FL market, with the plurality of this provider's patient population coming from Charlotte, FL. This provider's primary affiliated billing organization is JAY S. HERBST M.D., P.A. (NPI: 1033488424; TIN: 650384510) and primary practice location at 33952-5126.

Herbst's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,155 traditional Medicare patients, billed 13,569 HCPCS/CPT codes, and received $802,796 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 610 prescription claims across 336 beneficiaries totaling $9,784 in drug costs, led by Ketoconazole (Ketoconazole). Open Payments data shows 21 records totaling $528. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $30,561 to $9,784. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$401K$803K2015 Medicare payment: $710,425 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $634,385 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $649,696 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $606,108 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $714,965 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $655,950 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $686,352 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $640,980 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $771,191 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $802,796 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,1869,279$710,425
20161,1069,636$634,385
20171,0339,760$649,696
20181,0078,833$606,108
20191,03019,795$714,965
202096727,096$655,950
202191224,989$686,352
202277325,068$640,980
202390913,559$771,191
20241,15513,569$802,796

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$25K$50K2015 Drug cost: $30,561 (USD; Tot_Drug_Cst)2016 Drug cost: $27,085 (USD; Tot_Drug_Cst)2017 Drug cost: $22,203 (USD; Tot_Drug_Cst)2018 Drug cost: $19,815 (USD; Tot_Drug_Cst)2019 Drug cost: $12,124 (USD; Tot_Drug_Cst)2020 Drug cost: $12,259 (USD; Tot_Drug_Cst)2021 Drug cost: $33,829 (USD; Tot_Drug_Cst)2022 Drug cost: $49,569 (USD; Tot_Drug_Cst)2023 Drug cost: $46,834 (USD; Tot_Drug_Cst)2024 Drug cost: $9,784 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015334684$30,561
2016339660$27,085
2017293588$22,203
2018290556$19,815
2019260448$12,124
2020304551$12,259
2021277523$33,829
2022164309$49,569
2023224430$46,834
2024336610$9,784

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths310397$68
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more6471,070$67
11102Biopsy of related skin growth, first growth300362$57
17000Destruction of precancer skin growth, 1 growth437615$33
17003Destruction of precancer skin growth, 2-14 growths3492,555$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
KetoconazoleKetoconazole631,626$1,227
Betamethasone DipropionateBetamethasone Dipropionate43984$1,034
MetronidazoleMetronidazole27702$869
Clobetasol PropionateClobetasol Propionate19430$704
Triamcinolone AcetonideTriamcinolone Acetonide701,887$599

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.21$528Janssen Biotech, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Jay S. Herbst, M.D.?

Tedicare shows public-source Medicare data for Jay S. Herbst, M.D. (NPI 1710047097), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jay S. Herbst, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jay S. Herbst, M.D.?

Jay S. Herbst, M.D. is linked to JAY S. HERBST M.D., P.A. (billing NPI 1033488424) in the available physician profile data.

Does Jay S. Herbst, M.D. have Open Payments data?

Jay S. Herbst, M.D. has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.